Literature DB >> 30056728

Advances in chemotherapy for HER2-negative metastatic breast cancer.

Hirofumi Mukai1, Mayuko Ito2.   

Abstract

Metastatic breast cancer cannot be curable, but significant improvement in overall survival has been observed with the appearance of new agents. The purpose of treatment is to prolong survival and to improve quality of life by reducing cancer-related symptoms. To achieve these goals, individualized approach is required. Chemotherapy is used for patients with hormone receptor negative breast cancer or hormone receptor positive patients who have cancer-related symptoms. The choice of regimen (single-agent or a combination), selection of a specific therapy and the duration of treatment depend on multiple factors, including the tumor burden, general health status, prior treatments and toxicities, and patient preferences.

Entities:  

Keywords:  Breast cancer; chemotherapy; quality of life (QOL); survival

Mesh:

Substances:

Year:  2018        PMID: 30056728     DOI: 10.21037/cco.2018.06.01

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


  1 in total

1.  miR-221/222 promote tumor growth and suppress apoptosis by targeting lncRNA GAS5 in breast cancer.

Authors:  Yuanyuan Zong; Yazhou Zhang; Xichao Sun; Tao Xu; Xiankui Cheng; Yejun Qin
Journal:  Biosci Rep       Date:  2019-01-15       Impact factor: 3.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.